يعرض 1 - 10 نتائج من 30 نتيجة بحث عن '"Hansson, Markus"', وقت الاستعلام: 0.74s تنقيح النتائج
  1. 1
    مؤتمر
  2. 2
    مؤتمر
  3. 3
    مؤتمر

    المصدر: Abildgaard , N , Hansson , M , Anttila , P , Waage , A , Green , A , Rubin , K H , von Arx , L-B , Willock , R , a , Y , Ørstavik , S , Bent-Ennakhil , N , Jonatan Freilich , J , Gavini , F & Fast , T 2020 , ' REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILISATION, AND CLINICAL OUTCOMES FROM THE HUMANS STUDY IN MULTIPLE MYELOMA IN DENMARK, SWEDEN, AND FINLAND ' , 25th EHA Annual Congress , Frankfurt , Germany , 11/06/2020 - 21/06/2020 . < https://library.ehaweb.org/eha/2020/eha25th/294519/niels.abildgaard.real-world.treatment.patterns.healthcare.resource.utilization.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmultiple+myeloma+humansTest ....

  4. 4
    مؤتمر
  5. 5
    مؤتمر

    المصدر: Kongsgaard Nielsen , L , Schjesvold , F H , Möller , S , Guldbrandsen , N , Hansson , M , Remes , K , Peceliunas , V , Gregersen , H , King , M & Abildgaard , N 2023 , ' CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA ' , EHA 2023 Hybrid Conference , Frankfurt , Germany , 08/06/2023 - 11/06/2023 pp. 3245 .

  6. 6
    مؤتمر
  7. 7
    مؤتمر
  8. 8
    مؤتمر

    المصدر: Gregersen , H , Peceliunas , V , Remes , K , Schjesvold , F H , Abildgaard , N , Nahi , H , Andersen , N F , Vangsted , A J , Klausen , T W , Helleberg , C , Carlson , K , Frølund , U , Axelsson , P , Stromberg , O , Blimark , C , Linder , O , Tsykunova , G , Waage , A , Hansson , M & Guldbrandsen , N 2019 , ' Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASCT in multiple ....

  9. 9
    مؤتمر

    المصدر: Spencer , A , Iversen , K F , Dhakal , B , Creignou , M , Chen , J , Hiemstra , I H , Bosgra , S , Badani , A , Breij , E C W , Brady , L K , Sasser , A K , Malmberg , A , Gregersen , H , Hansson , M , Broijl , A , Mateos , M-V & Plesner , T 2022 , ' Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody (R)-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ' ....

  10. 10
    مؤتمر